Citadel Advisors
DNLI icon

Citadel Advisors’s Denali Therapeutics DNLI Stock Holding History

Citadel Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.48M Buy
+129,300
New +$2.57M ﹤0.01% 5638
2025
Q3 		– Sell
-15,400
Closed -$215K – 13014
2025
Q2 		$215K Buy
15,400
+7,500
+95% +$106K ﹤0.01% 10519
2025
Q1 		$107K Buy
7,900
+1,100
+16% +$21.1K ﹤0.01% 11356
2024
Q4 		$139K Buy
6,800
+2,100
+45% +$53.8K ﹤0.01% 11006
2024
Q3 		$137K Sell
4,700
-3,600
-43% -$89.2K ﹤0.01% 10684
2024
Q2 		$193K Sell
8,300
-2,200
-21% -$42.2K ﹤0.01% 9993
2024
Q1 		$215K Buy
10,500
+8,000
+320% +$150K ﹤0.01% 10159
2023
Q4 		$53.6K Sell
2,500
-1,100
-31% -$21.8K ﹤0.01% 11713
2023
Q3 		$74.3K Buy
3,600
+3,000
+500% +$76.1K ﹤0.01% 11260
2023
Q2 		$17.7K Sell
600
-11,400
-95% -$321K ﹤0.01% 12840
2023
Q1 		$276K Buy
12,000
+3,000
+33% +$82.6K ﹤0.01% 9539
2022
Q4 		$250K Buy
9,000
+900
+11% +$26.8K ﹤0.01% 9695
2022
Q3 		$249K Buy
8,100
+1,000
+14% +$32.5K ﹤0.01% 9971
2022
Q2 		$209K Buy
+7,100
New +$186K ﹤0.01% 10612
2022
Q1 		– Sell
-38,900
Closed -$1.74M – 13769
2021
Q4 		$1.74M Buy
38,900
+20,000
+106% +$948K ﹤0.01% 6578
2021
Q3 		$954K Buy
18,900
+3,600
+24% +$203K ﹤0.01% 8277
2021
Q2 		$1.2M Sell
15,300
-2,700
-15% -$167K ﹤0.01% 7866
2021
Q1 		$1.03M Buy
18,000
+3,700
+26% +$248K ﹤0.01% 8037
2020
Q4 		$1.2M Buy
14,300
+7,400
+107% +$447K ﹤0.01% 6409
2020
Q3 		$247K Buy
+6,900
New +$208K ﹤0.01% 8457
2020
Q2 		– Sell
-12,300
Closed -$215K – 9894
2020
Q1 		$215K Sell
12,300
-900
-7% -$18.8K ﹤0.01% 7894
2019
Q4 		$230K Buy
13,200
+2,000
+18% +$33.3K ﹤0.01% 7984
2019
Q3 		$172K Buy
+11,200
New +$214K ﹤0.01% 8232

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's DNLI Position: Q1 2026 in Review

Citadel Advisors reduced its Denali Therapeutics (DNLI) stake by 77% in Q1 2026, selling an estimated $11.9M and leaving 181,417 shares worth $3.48M. The position accounts for ﹤0.01% of the portfolio, ranked #4969.

Citadel Advisors first reported a position in DNLI in Q2 2018 and has held it in 29 quarters since. The position peaked at $31.7M in Q1 2023. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Citadel Advisors held 181,417 shares of Denali Therapeutics worth $3.48M as of Q1 2026.
  • Citadel Advisors sold 597,731 Denali Therapeutics shares in Q1 2026, an estimated $11.9M.
  • Denali Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4969 holding.
  • Citadel Advisors first reported a position in Denali Therapeutics in Q2 2018 and has held it in 29 quarters since.
  • Citadel Advisors's Denali Therapeutics position peaked at $31.7M in Q1 2023.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.